Key Points
- Director Gilbert Fuller sold 1,057 shares of USANA Health Sciences on May 22 at an average price of $18.66, totaling about $19,724.
- USANA shares were down 1.9% and opened at $18.38, near their 50-day moving average of $18.24 and below the 200-day average of $19.48.
- The company beat quarterly earnings and revenue estimates, reporting $0.61 EPS versus $0.44 expected and $250.22 million in revenue versus $240.99 million expected, while analysts currently have an average rating of “Reduce”.
USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) Director Gilbert Fuller sold 1,057 shares of the business's stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $18.66, for a total value of $19,723.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
USANA Health Sciences Trading Down 1.9%
NYSE USNA opened at $18.38 on Wednesday. The stock's 50-day moving average price is $18.24 and its two-hundred day moving average price is $19.48. The company has a market cap of $339.35 million, a PE ratio of 39.11, a PEG ratio of 0.74 and a beta of 0.77. USANA Health Sciences, Inc. has a 1 year low of $16.60 and a 1 year high of $38.32.
USANA Health Sciences (NYSE:USNA - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.17. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.The company had revenue of $250.22 million for the quarter, compared to analysts' expectations of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Research analysts forecast that USANA Health Sciences, Inc. will post 2.12 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the company. Zacks Research cut USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 22nd. Wall Street Zen cut USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday, May 2nd. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of USANA Health Sciences in a research note on Friday, March 27th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Reduce".
Check Out Our Latest Report on USANA Health Sciences
Hedge Funds Weigh In On USANA Health Sciences
Several institutional investors and hedge funds have recently bought and sold shares of the business. National Bank of Canada FI grew its stake in shares of USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company's stock valued at $53,000 after buying an additional 1,201 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company's stock valued at $73,000 after buying an additional 1,901 shares in the last quarter. State of Wyoming bought a new stake in shares of USANA Health Sciences in the 1st quarter valued at approximately $57,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of USANA Health Sciences by 52.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company's stock valued at $106,000 after buying an additional 1,327 shares in the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of USANA Health Sciences by 1,354.3% in the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company's stock valued at $76,000 after buying an additional 3,589 shares in the last quarter. Hedge funds and other institutional investors own 54.25% of the company's stock.
About USANA Health Sciences
(
Get Free Report)
USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.
Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
